| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q4 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Protagonist Therapeutics, Inc. | 8 | Q3 2018 | 50.6% |
| Argos Therapeutics Inc. | 8 | Q3 2018 | 55.9% |
| Proteon Therapeutics Inc. | 8 | Q3 2018 | 15.8% |
| Argos Therapeutics Inc. | 8 | Q3 2018 | 23.6% |
| Jounce Therapeutics, Inc. | 7 | Q3 2018 | 38.8% |
| Allena Pharmaceuticals | 4 | Q3 2018 | 45.9% |
| Neon Therapeutics Inc. | 1 | Q3 2018 | 17.3% |
View Pharmstandard International S.A.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Allena Pharmaceuticals, Inc. | November 15, 2018 | 873,031 | 4.2% |
| Protagonist Therapeutics, Inc | February 21, 2018 | 982,270 | 4.8% |
| ARGOS THERAPEUTICS INC | June 26, 2017 | 18,362,883 | 39.9% |
| PROTEON THERAPEUTICS INC | February 12, 2015 | 1,165,344 | 7.1% |
View Pharmstandard International S.A.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2018-11-15 |
| SC 13G | 2018-11-15 |
| 13F-HR | 2018-08-14 |
| 13F-HR | 2018-05-15 |
| SC 13G/A | 2018-02-21 |
| SC 13G | 2018-02-15 |
| 13F-HR | 2018-02-14 |
| 13F-HR | 2017-11-03 |
| 4 | 2017-11-02 |
| 13F-HR/A | 2017-08-17 |
View Pharmstandard International S.A.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.